New law goes into effect on July 1 authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today hailed a new Florida law taking effect today that opens the door to physicians' use of investigational stem cell therapies in the state in orthopedics, wound care, and pain manag ...

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa's transition from research to clinical-stage development. This come ...

Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under the previously announced securities purchase agreement (the "SPA") entered into on March 31, 2025 with certain accredited investors. The ...

核心观点 - BrainStorm Cell Therapeutics公布了NurOwn®在ALS患者中的新生存数据 显示90%的参与者(9/10)存活超过5年 远高于通常ALS患者约10%的五年存活率 [1][7] - 中位生存期为6 8年(范围6-7年) 其中6名患者在症状出现后7年仍存活 这些数据支持即将开展的3b期临床试验 [4][7] - 公司高管表示这些结果提供了真实世界的证据 支持NurOwn在ALS治疗中的潜在临床价值 并强调了与FDA达成SPA协议的重要性 [4] 临床试验数据 - 扩展访问计划(EAP)纳入了10名完成3期临床试验的ALS患者 基线平均ALSFRS-R评分为35 8(范围32-40) EAP开始时降至31 4(范围27-38) [2] - 观察到的生存期显著长于典型ALS患者 仅1例死亡为选择性安乐死 其余9例均超过5年生存期 [7] - 这些数据为即将开展的注册性3b期对照临床试验提供了科学依据 [4] 产品与技术 - NurOwn®是自体MSC-NTF细胞技术平台 通过分泌高水平神经营养因子(NTFs)和免疫调节细胞因子 靶向神经退行性疾病的病理机制 [5] - 该技术已获得FDA和EMA的孤儿药认定 用于ALS治疗 [8] - 除ALS外 公司还在进行多发性硬化症(MS)的2期临床试验 并开发基于外泌体的异体治疗平台 [8] 公司发展 - BrainStorm专注于开发成人干细胞疗法治疗神经退行性疾病 核心平台为NurOwn®技术 [6] - 公司近期获得美国专利商标局关于外泌体技术的专利授权 加强了再生医学领域的知识产权组合 [8] - 已完成ALS的3期临床试验(NCT03280056) 即将启动与FDA达成SPA协议的3b期试验 [8]